ADC Therapeutics SA
ADCT
$1.29
-$0.01-0.77%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.03% | 4.43% | 14.85% | 6.35% | 15.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.03% | 4.43% | 14.85% | 6.35% | 15.73% |
| Cost of Revenue | -27.34% | -14.37% | -5.74% | -1.50% | 8.55% |
| Gross Profit | 79.48% | 49.14% | 39.48% | 13.09% | 1.90% |
| SG&A Expenses | 4.93% | -1.52% | -6.61% | -11.74% | -12.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.45% | -9.02% | -6.11% | -5.92% | -0.96% |
| Operating Income | 25.13% | 17.23% | 17.61% | 12.20% | 8.99% |
| Income Before Tax | 42.34% | 9.04% | 10.19% | 1.57% | 1.56% |
| Income Tax Expenses | -134.01% | 405.95% | 511.45% | -97.48% | -97.27% |
| Earnings from Continuing Operations | 42.98% | 8.58% | 9.64% | 21.31% | 20.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.98% | 8.58% | 9.64% | 21.31% | 20.92% |
| EBIT | 25.13% | 17.23% | 17.61% | 12.20% | 8.99% |
| EBITDA | 24.59% | 16.76% | 17.30% | 12.12% | 9.13% |
| EPS Basic | 54.81% | 24.29% | 27.55% | 39.57% | 38.41% |
| Normalized Basic EPS | 52.60% | 33.24% | 35.21% | 29.88% | 29.11% |
| EPS Diluted | 54.81% | 24.29% | 27.55% | 39.57% | 38.41% |
| Normalized Diluted EPS | 52.60% | 33.24% | 35.21% | 29.88% | 29.11% |
| Average Basic Shares Outstanding | 31.95% | 27.73% | 30.69% | 26.67% | 25.78% |
| Average Diluted Shares Outstanding | 31.95% | 27.73% | 30.69% | 26.67% | 25.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |